Dovitinib dilactic acid, identified by the CAS number 852433-84-2, is a chemical compound that serves primarily as a kinase inhibitor, targeting various receptor tyrosine kinases involved in tumor growth and angiogenesis. It is a derivative of dovitinib, which is known for its potential in cancer therapy, particularly in treating solid tumors. The dilactic acid component suggests that the compound may have enhanced solubility and bioavailability, which are critical for therapeutic efficacy. Dovitinib dilactic acid typically exhibits characteristics such as moderate to high stability under physiological conditions, and its pharmacokinetic profile may include oral bioavailability and a favorable half-life. The compound's mechanism of action involves the inhibition of specific signaling pathways that are crucial for cancer cell proliferation and survival. As with many pharmaceutical compounds, its safety and efficacy are evaluated through clinical trials, and it may have specific storage and handling requirements to maintain its integrity. Overall, dovitinib dilactic acid represents a promising avenue in targeted cancer therapy.

Dovitinib Dilactic acid

852433-84-2: Dovitinib dilactic acid, identified by the CAS number 852433-84-2, is a chemical compound that serves primarily as a kinase inhibitor, targeting various receptor tyrosine kinases involved in tumor growth and angiogenesis. It is a derivative of dovitinib, which is known for its potential in cancer therapy, particularly in treating solid tumors. The dilactic acid component suggests that the compound may have enhanced solubility and bioavailability, which are critical for therapeutic efficacy. Dovitinib dilactic acid typically exhibits characteristics such as moderate to high stability under physiological conditions, and its pharmacokinetic profile may include oral bioavailability and a favorable half-life. The compound's mechanism of action involves the inhibition of specific signaling pathways that are crucial for cancer cell proliferation and survival. As with many pharmaceutical compounds, its safety and efficacy are evaluated through clinical trials, and it may have specific storage and handling requirements to maintain its integrity. Overall, dovitinib dilactic acid represents a promising avenue in targeted cancer therapy.

DOVITINIB DILACTIC ACID (TKI258 DILACTIC ACID)

Dovitinib dilactic acid: multitarget RTK inhibitor for FLT3/c-Kit (IC50=1-2 nM), FGFR1/3, VEGFR1-4 (IC50=8-13 nM), less effective on InsR, EGFR. Phase 4.

CAS 852433-84-2

Dovitinib Dilactic acid

DOVITINIB DILACTIC ACID (TKI258 DILACTIC ACID)

Ref: IN-DA00G6VJ

Dovitinib Dilactic Acid

Ref: TM-T6193